GENE ONLINE|News &
Opinion
Blog

2018-12-02| PartnerAsia-Pacific

Med x Tech Summit Asia 2018: Day 1 Recap

by GeneOnline
Share To

By Joanne Shih

Med x Tech Summit Asia (MEDTEX) opened on November 30 together with the Taiwan Healthcare+ Expo 2018 in Taipei, Taiwan.

Su, Jia-Chyuan, President of the Legislative Yuan, remarked at the opening of MEDTEX summit. Su announced the signage of new MOUs to prompt in-depth collaborations with international partners. Six MOUs were signed by the Institute of Biotechnology and Medicine Industry (IBMI) with associations from Thailand, Australia, Malaysia, and Korea, including Federation of Thai Industries (FTI), Thai Medical informatics Association, Private Hospital Association Thailand, Chungbuk Leader’s Club, Medical Software Industry Association of Australia, and Malaysia Association for Cell Therapy. Forums discussing from immune-oncology, to next generation bio-therapeutics, and to digital healthcare were carried in the following programs.

Su, Jia-Chyuan, President of the Legislative Yuan, remarked at the opening of MEDTEX summit. (Photo credit/GeneOnline)
Su, Jia-Chyuan, President of the Legislative Yuan, remarked at the opening of MEDTEX summit. (Photo credit/GeneOnline)

Novel Bio-therapeutics in Practice

In the session of Immuno-Oncology, Next-generation Bio-therapeutics, and Gene Editing, Wise Young, Chief Science and Medical Advisor at StemCyte, talked about stem cell transplantation in spinal cord injured patients and advocated “666 Walking Program” for treating such patients. Special Program Director at Takeda Pharmaceutical, Seigo Izumo gave an overview of how Takeda uses iPSC in multiple dimensions, including cell therapy, drug discovery, and gene editing therapy. Tony J. Wang from the Columbia University Medical Center then talked about chemo-radiation which combines immunotherapy and radiation to treat brain tumor with outstanding results. David DiGiusto, CTO at Semma Therapeutics, brought up the importance of minimizing risks of cell therapy and gene editing clinical trials, and illustrated a review and assessment process that’s been practiced in Semma Therapeutics.

CEOs Perspectives

At the CEO Forum, leaders from pharmaceutical and IT companies, including Merck, Teva, Hitachi, NVIDIA, and Qisda talked about the future of healthcare industry and intersectional possibilities. Many of them emphasized collaboration and partnership are the key to build a thriving future. To stay innovative is also crucial to pharmaceutical and healthcare industry. Birgit Reitmaier, Head of Access to Innovation APAC at Merck, said, “Diversity is the key to constantly stay innovative. Internally we keep an open eye, but externally keep scouting to outer world.”

The CEO of Mammoth Bioscience, Trevor Martin had a fireside conversation with Chris Shu, the Managing Partner at Pacific 8 Ventures discussing CRISPR from its basic principle, to its advantages, and to the current ethical controversy in China. Trevor Martin pointed out that CRISPR has an great impact on human society, so mankind should be more transparency and fully communicate when dealing with this powerful technology.

Leaders from pharmaceutical and IT companies, including Merck, Teva, Hitachi, NVIDIA, and Qisda talked about the future of healthcare industry and intersectional possibilities. (Photo credit/GeneOnline)
Leaders from pharmaceutical and IT companies, including Merck, Teva, Hitachi, NVIDIA, and Qisda talked about the future of healthcare industry and intersectional possibilities. (Photo credit/GeneOnline)

Delivering Personalized Healthcare through Precision Medicine

IBM Watson Health, Harvard Medical School, and Vancouver Prostate Centre also joined this meeting to talk about personalized healthcare from different dimensions. Lenny Chen from IBM Watson Health, said that their goal is to create collaboration between human and machine instead of trying to replace human with machine. Alireza Haghighi, Clinician Scientists at Harvard Medical School, called that, “The DNA data we have is too white” to point out currently the genome data we have is mostly from western population which is not enough to develop a comprehensive medical solution. Colin Collins from Vancouver Prostate Centre, the Director of Laboratory for Advanced Genome Analysis, addressed precision oncology in treating prostate cancer. Collins said, “The key to precision oncology is to understand how to treat patient with different drugs based on genomic profile of patients’ prostate cancer. We now are not doing this very well, but we can do it. We just need to think up a sustainable way toward precision medicine.”

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Biomedical& ICT, Taiwan Aims to Lead the Digital Healthcare Market
2019-12-18
Med X Tech Summit Asia (MEDTEX) 2018 – Overview of Day 1 Program
2018-11-22
【Event Information】Med x Tech Summit Asia (MEDTEX) will debut on Nov 29th – 30th in Taipei, Taiwan!
2018-10-04
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top